OTCMKTS:ARPOAerpio Pharmaceuticals Stock Price, Forecast & News

$1.18

+0.07 (+6.31 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.10

Now: $1.18▼

$1.22

50-Day Range

$0.52

MA: $0.74▼

$1.13

52-Week Range

$0.42

Now: $1.18▼

$1.53

Volume2.24 million shs

Average Volume1.32 million shs

Market Capitalization$47.89 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Aerpio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.00, Aerpio Pharmaceuticals has a potential downside of 15.3% from its current price of $1.18.
Amount of Analyst Coverage
Aerpio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Aerpio Pharmaceuticals has received 96 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aerpio Pharmaceuticals has received 99 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aerpio Pharmaceuticals has received 50.77% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARPO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aerpio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aerpio Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aerpio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.60% of the stock of Aerpio Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.37% of the stock of Aerpio Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.90 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:ARPO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.aerpio.com

Phone513-985-1920

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares40,588,000

Market Cap$47.89 million

Next Earnings DateN/A

OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions

How has Aerpio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARPO stock has increased by 118.5% and is now trading at $1.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aerpio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aerpio Pharmaceuticals.

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. View Aerpio Pharmaceuticals' earnings history.

What price target have analysts set for ARPO?

1 brokerages have issued 1-year price targets for Aerpio Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Aerpio Pharmaceuticals' stock price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 15.3%. View analysts' price targets for Aerpio Pharmaceuticals.

What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:

1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (2/13/2020)
2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019)

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

News headlines about ARPO stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aerpio Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

Some companies that are related to Aerpio Pharmaceuticals include Kezar Life Sciences (KZR), Kindred Biosciences (KIN), Avenue Therapeutics (ATXI), NeuBase Therapeutics (NBSE), Aquestive Therapeutics (AQST), Tyme Technologies (TYME), Scpharmaceuticals (SCPH), IDEAYA Biosciences (IDYA), Cerecor (CERC), Tiziana Life Sciences (TLSA), CELYAD SA/ADR (CYAD), PhaseBio Pharmaceuticals (PHAS), Evolus (EOLS), Galectin Therapeutics (GALT) and Minerva Neurosciences (NERV). View all competitors.

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), MannKind (MNKD), BIOLINERX LTD/S (BLRX), Actinium Pharmaceuticals (ATNM), AVEO Pharmaceuticals (AVEO), Biocept (BIOC), Catalyst Pharmaceuticals (CPRX), General Motors (GM) and Ovid Therapeutics (OVID).

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the following people:

Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
Dr. Stephen J. Hoffman, CEO & Director (Age 64)
Mr. Michael W. Rogers, Chief Financial Officer (Age 58)

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.18.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $47.89 million.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is www.aerpio.com.

How can I contact Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff